������ϲ�����

Fund manager Tarek Sherif moved into a small office with young tech entrepreneur and researcher, Glen de Vries, who hand-coded ������ϲ�����’s original software. The two worked with Ed Ikeguchi and founded ������ϲ����� in 1999.

The collection of data in clinical trials was forever changed by the launch of Rave, the first software to digitally collect clinical trial data. Later named Rave EDC (Electronic Data Capture), it quickly becomes the most advanced, robust, and secure EDC system for clinical trial site, patient, and lab data capture and management in the world.

From customer requests for a Rave users forum to share best practices in the use of the solution, the ������ϲ����� User Group (MUG) was born. As the annual event grew in both attendance and scope, MUG was rebranded as ������ϲ����� Symposium in 2015 and as ������ϲ����� NEXT in 2017. ������ϲ����� NEXT brings together key industry leaders, change-makers, and patient advocates to shape the future of life sciences.

The acquisition of Clinical Force adds ������ϲ����� CTMS^® (clinical trial management system) to solutions.

The acquisition of Mytrus adds eConsent to the ������ϲ����� Rave^® Platform.

The acquisition of CHITA adds regulated content management and eTMF capabilities to the ������ϲ����� Rave^® Platform.

The acquisition of SHYFT Analytics, powers ������ϲ����� customers’ digital transformation with AI and real-world analytics.

������ϲ����� AI launched in 2019, combining data, technology, and deep expertise to help life sciences companies deliver actionable insights across the entire continuum of clinical development. ������ϲ����� AI’s advanced analytics answers the most important questions in R&D and commercialization including accelerating breakthrough innovation, optimizing study execution and commercial success, and demonstrating the value of therapies.

Dassault Systèmes, the 3DEXPERIENCE Company, acquired ������ϲ����� to drive the digital transformation of life sciences in the age of personalized medicine and patient-centric experience. Through this combination, the companies will push the boundaries of innovation, learning and production to achieve a more sustainable world for patients, citizens, and consumers.

Over the course of 2020, ������ϲ����� published nine White Papers detailing the implications of COVID-19 on existing and new drug and vaccine studies. COVID-19 and Clinical Trials: The ������ϲ����� Perspective also reviewed the impact on patients, and shared a range of solutions to support the continuation of current clinical studies around the world.

Built for patients, by patients, my������ϲ����� is an award-winning single destination patient portal, allowing patients to use any online device to virtually learn, enroll and engage in clinical trials. Only my������ϲ����� enables the full range of tools to build scalable, flexible solutions at every level of decentralized and hybrid clinical trials.

������ϲ�����’s suite of technologies supported the advancement of Moderna’s mRNA-1273 clinical trials, including the Phase 3 trial, which enrolled more than 30,000 participants. The ������ϲ����� and Moderna teams moved forward with the speed and urgency necessitated by the global pandemic, using ������ϲ�����’s innovative and scalable cloud platform for clinical development.

In a regulatory first, the US Food and Drug Administration (FDA) allowed Medicenna Therapeutics, Corp. to use a hybrid external control arm in a phase 3 registrational trial. The phase 2 single arm trial preceding this phase 3 study in recurrent glioblastoma, an aggressive form of brain cancer, was also enhanced by a synthetic control arm.

������ϲ����� Launches my������ϲ����� Registries, a new technology that expands and strengthens the my������ϲ����� patient portal to engage patients before and after (i.e., long term follow up/safety surveillance) a clinical trial.

������ϲ����� launched the most comprehensive set of unified, secure technologies that enable decentralized clinical trials (DCTs) across the development continuum. For the first time ever, drug, vaccine, and medical device developers (sponsors) and contract research organizations (CROs) can take advantage of the only platform offering on the market.

������ϲ����� Sensor Cloud provides cutting-edge common data models and proprietary algorithms enabling rapid ingestion, normalization and analysis of patient data resulting in better clinical decision making, faster timelines and a more patient-centric experience.

The Sensor Cloud Network, creating the first industry-wide collaboration amongst contract research organizations (CROs), device manufacturers, drug and vaccine developers, analytics companies, and academia, was launched in October 2021.

������ϲ����� Rave Imaging, the company’s cloud-based, secure clinical trial imaging management platform, reached a significant milestone, having supported more than 1,000 imaging studies. Rave Imaging, built on the ������ϲ����� Unified Platform, processes more than 100 million images annually.

Glen de Vries, co-founder of ������ϲ�����, died in a plane crash, weeks after fulfilling his lifelong dream of traveling to space. Glen had an incredible impact on the life science industry and left a lasting legacy of improving the clinical development process, bringing new drugs, vaccines, and diagnostics – and hope – to patients around the world.

������ϲ����� announced it is allowing sponsors, CROs (contract research organizations), and sites to leverage its proprietary Patient Insights Program. The program infuses the patient perspective into the software development life cycle to create technical solutions that improve the overall patient experience in clinical research operations.

������ϲ����� Becomes First Life Sciences Technology Company to Exceed 30,000 Clinical Trials and 9 Million Study Volunteers.